Polyrizon Ltd.
PLRZNasdaq
$13.42
↑ +3.2%Jul 17 close · end-of-day
Price
1Y↑ +113.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$9.1M
Enterprise Value
$7.8M
P/E
2.7
P/S
—
P/B
0.4
EV/EBITDA
—
PEG
0.0
FCF Yield
-49.7%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$3.3M
Free Cash Flow (TTM)
-$4.5M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-15.9%
ROIC
-25.1%
Debt / Equity
—
Net Cash
$1.3M
Return 1Y
+130.7%
Company profile
We are a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. We are an Israeli corporation, incorporated in January 2005. Our principal executive offices are located at 5 Ha-Tidhar Street, Raanana, 4366507, Israel.
- CEO
- Tomer Izraeli
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- Illinois
- Website
- polyrizon-biotech.com
Management & directors
- Izraeli TomerChief Executive Officer
- Turgeman TidharChief Technology Officer
Roles derived from SEC Form 4 filings.
Earnings
No reported earnings periods on file.
Financial statements
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$895,000.00 | -$635,000.00 | -$1.3M | -$6.2M |
| Net income | -$779,000.00 | -$600,000.00 | -$1.5M | -$3.3M |
| Diluted EPS | $0.60 | $494.40 | $805.20 | $4.90 |
| Operating cash flow | -$1.1M | -$537,000.00 | -$1.1M | -$4.5M |
| Free cash flow | -$1.1M | — | — | -$4.5M |
| Gross margin | — | — | — | — |
| Operating margin | — | — | — | — |
| Net margin | — | — | — | — |
No quarterly data.
Company news
Jul 2, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-03-31 | Adler Oz | Sale | 3,292 | $12.05 | $39,668.60 | filing |
| 2026-03-31 | Carmel Liron | Sale | 942 | $12.36 | $11,643.12 | filing |
| 2026-03-31 | Izraeli Tomer· Chief Executive Officer | Sale | 500 | $11.85 | $5,925.00 | filing |
| 2026-03-30 | Izraeli Tomer· Chief Executive Officer | Sale | 3,900 | $10.90 | $42,510.00 | filing |
| 2026-03-30 | Turgeman Tidhar· Chief Technology Officer | Sale | 2,917 | $10.90 | $31,795.30 | filing |
| 2026-03-30 | Carmel Liron | Sale | 100 | $11.00 | $1,100.00 | filing |
Latest 6 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.